New Shire Board Member

Wednesday, November 4, 2009 General News J E 4
DUBLIN, Ireland, November 2 The Board ofDirectors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr DavidStout joined the Board as a Non Executive Director with effect from 31October 2009.

Mr Stout has extensive pharmaceutical experience. Most recently he wasPresident, Pharmaceutical Operations at GSK. In this position he hadresponsibility for pharmaceutical operations in the United States, Europe,Japan and all other International Markets. Mr Stout was also responsible forglobal manufacturing and global Biologics (vaccines) at GSK. Prior to that hewas President of GSK's US Pharmaceuticals Business and before that SmithKlineBeecham's North American Pharmaceuticals Business. Before joining SmithKlineBeecham, Mr Stout worked for many years at Schering-Plough.

Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit,Inc. and Airgas Inc.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He bringswith him extensive international experience in the pharmaceutical industry,which we believe will be of great value to Shire as it continues its growthtrajectory and becomes a more global company."

Notes to Editors


Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit hyperactivitydisorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)diseases as well as opportunities in other therapeutic areas to the extentthey arise through acquisitions. Shire's in-licensing, merger and acquisitionefforts are focused on products in specialist markets with strongintellectual property protection and global rights. Shire believes that acarefully selected and balanced portfolio of products with strategicallyaligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: further information please contact: Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-617-551-9715 Media Jessica Mann (Rest of the World) +44-1256-894-280 Matthew Cabrey (North America, +1-484-595-8248 Specialty Pharma) Jessica Cotrone (North America, HGT) +1-617-613-4640

SOURCE Shire Plc


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Medela Recognizes National Prematurity Awareness M...
Simcere Pharmaceutical Group to Announce 2009 Thir...